Claims
| Claim | Type | Assessment | Score | Review checks | References |
|---|---|---|---|---|---|
| In the NHS-Galleri trial's evaluable intervention participants across three annual rounds, the multi-cancer early-detection test had 99.50–99.60% specificity and 26.7–37.2% episode sensitivity for all cancers; these performance analyses were descriptive and the trial's primary late-stage-cancer endpoint was not met. | QUANTITATIVE | Supported | 0.9925 | 1 of 4 | 142 |